In about 15 to 50% of patients with advanced non-squamous non-small cell lung cancer (NSCLC), tumors harbor activating mutations in the epidermal growth factor receptor gene (EGFR), with relevant clinical and therapeutic implications that make this patient population peculiar [1,2]. Here, EGFR is linked to non-small cell lung carcinoma.